Updates

February 22, 2021February 22, 2021
Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

Enhertu (trastuzumab deruxtecan) has been granted conditional approval in the U.K. for the treatment of adults with inoperable or metastatic HER2-positive breast cancer who have received two ... Read more
February 18, 2021February 18, 2021
Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC

An open-label Phase 2 clinical trial will test the safety and efficacy of IRX-2, an experimental immunology-based cancer therapy, in combination with Keytruda (pembrolizumab) and ... Read more
February 15, 2021February 15, 2021
Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer

Seagen’s Tukysa (tucatinib) has been approved by the European Commission (EC) as part of a triple-combination therapy for people with previously treated advanced or metastatic HER2-positive ... Read more
February 11, 2021February 11, 2021
Trial Testing AL101 in TNBC Doses First Patient

The first participant has been dosed in the Phase 2 clinical trial TENACITY, which is evaluating Ayala Pharmaceuticals‘ investigational therapy AL101 as a treatment for ... Read more
February 8, 2021February 8, 2021
‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer

After promising results from patients enrolled to date, Atossa Therapeutics halted an Australian Phase 2 clinical trial evaluating its investigative oral therapy Endoxifen in women ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

June 22, 2018June 22, 2018

Clinical Trial of Tamoxifen-based Gel in Reducing Breast Density Recruiting in US, EU

News

The ability of a gel containing a tamoxifen-byproduct to reduce breast density — associated with an increased risk of breast cancer — is now being evaluated in a recruiting Phase 3 clinical trial. Approximately half of women in the ... Read more

Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC

Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer

Trial Testing AL101 in TNBC Doses First Patient

‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer

Theralink Begins Testing New Biomarker Assay for Breast Cancer Tumors

US Study Enrolling Women to Help Determine Best Screening Practices

Nonprofit Highlights Importance of Global Teamwork for World Cancer Day

Enhertu Approved in EU for Inoperable, Advanced Breast Cancer

Imagio Imaging System for Breast Cancer Diagnosis Approved by FDA

Mindfulness Can Alter Brain’s Perception of Pain in Cancer Survivors

Subscribe to our mailing list

Genetic Test for Advanced Breast Cancer Launched in EU

Breast Cancer Vaccine Cleared by FDA for Human Testing

ARX788 on FDA Fast Track for Advanced HER2-positive Breast Cancers

Conditional Approval Urged in EU for Trastuzumab Deruxtecan

Margenza Approved in US for Pretreated HER2-positive Breast Cancer

Antibody-drug Combo Shows Early Promise in Targeting Cancers, Company Says

Computer Model Uses Enzyme Organization to Predict Early Breast Cancer Recurrence

‘Unassuming’ Non-medicinal Plant Can Stop Growth of Breast Cancer Cells, Study Shows

Onconova Seeking FDA Approval for Phase 1 Trial of ON 123300 for Breast Cancer

Anixa Biosciences, Cleveland Clinic Developing Breast Cancer Vaccine

FDA Gives Breakthrough Device Status to 4D Path’s Breast Cancer Diagnostic Platform

New $100M Program Aims to Improve Diversity in Clinical Trials

FDA Grants Fast Track Status, Rolling Review to Lumicell’s LUM Imaging System

FDA Approves Keytruda-chemo Combo for Advanced TNBC Positive for PD-L1

Breast Cancer Cell Sugars in Liquid Biopsies Could Be Key to Early Detection

Athenex Oncology Offers Free ‘Evidenced-based’ Lifestyle Guide for MBC Patients

Phase 3 Trial to Compare Enhertu to Kadcyla in HER2-Positive, High Risk Patients

FDA Approves FoundationOne Liquid CDx as Companion Diagnostic Test for Piqray Treatment

FDA Grants Fast Track to PC14586, Potential Therapy for Specific p53 Mutation

Adding Ibrance to Hormone Therapy Fails to Prolong Time Before Cancer Recurs, Trial Shows

COVID-19 Surgery Delays May Mean 2,700 More Breast Cancer Deaths Within 10 Years

Signatera Test for Residual Disease Will Be Used in New Phase 2 Breast Cancer Trial

Trodelvy Shows Superiority to Chemo for Advanced TNBC in Phase 3 Trial

MammaCare Foundation Offers Simulator Training for Manual Breast Exams

FDA Puts Eganelisib on Fast Track for Advanced Triple-negative Breast Cancer

Activities Abound for Breast Cancer Awareness Month

Verzenio With Endocrine Therapy Can Lower Risk of Recurrence, Spread in Early Breast Cancer, Trial Shows

Clinical Trial Testing Estrogen Receptor Degrader GDC-9545 Enrolls First Participant

Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor

TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial Finds

First Patient Dosed in IRENE Trial Testing Immunotherapy-Oncolytic Virus Combo